Michael Broder

Michael Broder is a gay, white, HIV-positive man over 60 who grew up in Coney Island and now lives in Bed-Stuy, Brooklyn. He worked in HIV medical education alongside an inspiring generation of AIDS scientists, clinicians, advocates, and activists. He has been a freelance medical writer for the past two decades.

Related

Antiretroviral Therapy

More Virologic Failure Associated With Two-Drug Versus Three-Drug Regimens

A new retrospective observational study adds to the mounting body of evidence supporting three-drug combination therapy for complete virologic suppression.

Antiretroviral Therapy

More Virologic Failure Associated With Two-Drug Versus Three-Drug Regimens

A new retrospective observational study adds to the mounting body of evidence supporting three-drug combination therapy for complete virologic suppression.

Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF)

Weight Gain With Biktarvy About the Same as Other Popular INSTI-based Regimens

Starting antiretroviral for the first time with integrase strand inhibitor regimens has been associated with greater weight gain than regimens containing nonnucleoside reverse transcriptase inhibitors or boosted protease inhibitors.

Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF)

Weight Gain With Biktarvy About the Same as Other Popular INSTI-based Regimens

Starting antiretroviral for the first time with integrase strand inhibitor regimens has been associated with greater weight gain than regimens containing nonnucleoside reverse transcriptase inhibitors or boosted protease inhibitors.

HIV Treatments in Development

Long-Acting ART: What’s Here and What’s Ahead

We are likely to see more and more long-acting regimens coming into widespread use, says David Wohl, M.D., a professor of medicine at the University of North Carolina, Chapel Hill.

HIV Treatments in Development

Long-Acting ART: What’s Here and What’s Ahead

We are likely to see more and more long-acting regimens coming into widespread use, says David Wohl, M.D., a professor of medicine at the University of North Carolina, Chapel Hill.

Antiretroviral Therapy

Biktarvy 72-Week Trial Shows Effectiveness, Even In Those With Resistance

A 72-week trial from BRAAVE 2020 data demonstrated Biktarvy’s effectiveness in a cohort of Black people living with HIV, including those with pre-existing resistance, viral blips, and low adherence.

Antiretroviral Therapy

Biktarvy 72-Week Trial Shows Effectiveness, Even In Those With Resistance

A 72-week trial from BRAAVE 2020 data demonstrated Biktarvy’s effectiveness in a cohort of Black people living with HIV, including those with pre-existing resistance, viral blips, and low adherence.

Providing Quality HIV Care

Black Women Living With HIV Have Highest Rates of Early Death

A 21-year analysis by researchers at Vanderbilt University Medical Center presented at IDWeek 2021 found women had a higher risk of death than men—and Black women had the highest risk.

Providing Quality HIV Care

Black Women Living With HIV Have Highest Rates of Early Death

A 21-year analysis by researchers at Vanderbilt University Medical Center presented at IDWeek 2021 found women had a higher risk of death than men—and Black women had the highest risk.

Adverse Events & Comorbidities

IAS 2021 Data Bites: Comorbidities Among People Living With HIV

Larry Buhl; Michael Broder

The latest data on health complications among people living with HIV, including new findings on COVID-19 severity.

Adverse Events & Comorbidities

IAS 2021 Data Bites: Comorbidities Among People Living With HIV

Larry Buhl; Michael Broder

The latest data on health complications among people living with HIV, including new findings on COVID-19 severity.

Basic Science & Pathogenesis

Is Measuring Biological Age in People With HIV Clinically Useful?

A recent study finds that PLWH are more prone to faster epigenetic aging when compared to people without HIV—and that ART might partially reverse it.

Basic Science & Pathogenesis

Is Measuring Biological Age in People With HIV Clinically Useful?

A recent study finds that PLWH are more prone to faster epigenetic aging when compared to people without HIV—and that ART might partially reverse it.

HIV Care Continuum

Stable Housing Is Health Care For People Living With HIV

A recent study finds viral suppression rates and CD4+ cell counts were significantly lower among people experiencing homelessness.

HIV Care Continuum

Stable Housing Is Health Care For People Living With HIV

A recent study finds viral suppression rates and CD4+ cell counts were significantly lower among people experiencing homelessness.

Adverse Events & Comorbidities

A Smell Test May Help Disentangle Alzheimer’s From HIV-Associated Neurocognitive Disorder

A study suggests olfactory function may be a useful tool in distinguishing between HAND and a precursor for Alzheimer’s disease in older people living with HIV.

Adverse Events & Comorbidities

A Smell Test May Help Disentangle Alzheimer’s From HIV-Associated Neurocognitive Disorder

A study suggests olfactory function may be a useful tool in distinguishing between HAND and a precursor for Alzheimer’s disease in older people living with HIV.

Prevention Methods

HIV Data Bites: Recent Advances in Broadly Neutralizing Antibodies for HIV Prevention

While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.

Prevention Methods

HIV Data Bites: Recent Advances in Broadly Neutralizing Antibodies for HIV Prevention

While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.

HIV Care Continuum

Older Adults Living With HIV Often Have Delayed Entry Into Care

A new study shows that almost two-thirds of older adults who were diagnosed with HIV at a Connecticut clinic were already at an advanced stage of disease progression.

HIV Care Continuum

Older Adults Living With HIV Often Have Delayed Entry Into Care

A new study shows that almost two-thirds of older adults who were diagnosed with HIV at a Connecticut clinic were already at an advanced stage of disease progression.

PrEP (HIV Pre-Exposure Prophylaxis)

Injectable Long-Acting PrEP Is Safe, Highly Effective in Cisgender Women

The findings add to evidence that injectable PrEP could ultimately have greater real-world efficacy than daily oral PrEP in many populations, thanks to better adherence.

PrEP (HIV Pre-Exposure Prophylaxis)

Injectable Long-Acting PrEP Is Safe, Highly Effective in Cisgender Women

The findings add to evidence that injectable PrEP could ultimately have greater real-world efficacy than daily oral PrEP in many populations, thanks to better adherence.